LeMaitre Vascular, Inc. (LMAT) Stock Price & How to Invest

Last updated November 2026

Short answer

LMAT is LeMaitre Vascular, a Burlington, Massachusetts maker of devices used in open vascular surgery, and its shares trade on the Nasdaq like any other US-listed stock through a standard brokerage account. What defines the business is pricing rather than technology: about 7 of the 10 points of organic growth in the June 2026 quarter came from price and only 3 from volume, and the stock still sits near a 52-week low, closing at $81.89 on October 16, 2026, after management trimmed its full-year organic growth target in August.

LMAT stock price

As of 2026-11-16, LeMaitre Vascular, Inc. (LMAT) last closed at $77.01, down 11.5% over the past year. Over the past 52 weeks it has traded between $77.01 and $117.39.

LMAT last close
$77.01
1 day
-1.63%
1 month
-4.71%
1 year
-11.47%
52-week range
$77.01 to $117.39
Last close
2026-11-16

Prices are daily closing prices from Yahoo Finance and may be delayed. For the live quote, check your broker or LeMaitre Vascular, Inc.'s investor relations page. Walnut is informational, not investment advice.

LMAT key stats

At $77.01 on November 16, 2026, LeMaitre Vascular, Inc. (LMAT) has a market cap of $1.8B, a P/E of 28.0 on trailing earnings (24.4 on forward earnings) and a dividend yield of 1.30%.

Market cap
$1.8B
P/E (trailing)
28.0
P/E (forward)
24.4
EPS (trailing 12 months)
$2.75
Price to book
4.1
Dividend yield
1.30%
Beta
0.49

Market cap, P/E and yield are measured at the $77.01 price on November 16, 2026, from Yahoo Finance figures pulled in November 2026. Earnings date from Yahoo Finance. Walnut is informational, not investment advice.

What's new with LeMaitre Vascular, Inc. (LMAT)?

The last two weeks for LeMaitre Vascular, Inc., as of November 17, 2026: the price move, the next earnings date, what the company filed with the SEC, and what analysts changed.

  • LMAT closed at $77.01 on November 16, 2026, down 5.1% over the past five trading days (from $81.16).
  • On November 5, 2026, LeMaitre Vascular, Inc. filed its quarterly report (10-Q) with the SEC. Read the 10-Q on sec.gov
  • On November 4, 2026, LeMaitre Vascular, Inc. filed an 8-K with the SEC reporting quarterly results (Item 2.02). Read the 8-K on sec.gov
  • On November 5, 2026, Wells Fargo lowered its target to $86.00 from $94.00 (Equal-Weight).
  • On November 5, 2026, Citizens lowered its target to $110.00 from $127.00 (Market Outperform).

Prices are daily closes from Yahoo Finance. Filings are read from SEC EDGAR every six hours. Analyst actions come from Yahoo Finance as of November 2026. Walnut is informational, not investment advice.

LeMaitre Vascular, Inc. (LMAT) latest quarter

LeMaitre Vascular reported revenue of $68.0 million for Q3 2026, up 11% from a year earlier (LeMaitre Vascular, Nov 4, 2026).

Revenue
$68.0 million
up 11% from a year earlier
Diluted EPS (GAAP)
$0.65
down 13% from a year earlier
Americas
$42.7 million
up 9% from a year earlier

Source: LeMaitre Q3 2026 results, Nov 4, 2026. Full earnings breakdown

What does LeMaitre Vascular, Inc. (LMAT) do?

LeMaitre Vascular, founded in 1983 by vascular surgeon George LeMaitre, sells the unglamorous hardware of open vascular surgery: biologic patches, bovine carotid artery grafts sold as Artegraft, human vascular and cardiac allografts, carotid shunts, valvulotomes, embolectomy catheters and synthetic grafts. Roughly 163 direct sales representatives call on vascular surgeons in hospitals, which is the whole point of the model. Individual products are small line items with low average selling prices, too minor for a Medtronic or a Boston Scientific to defend aggressively, so LeMaitre buys niche lines (Restore Flow allografts in 2016 for ~$14M, Artegraft in 2020 for ~$90M), pushes them through its own rep force, and raises prices steadily.

The financial result of that approach is a gross margin above 72% and an operating margin near 29%, on trailing revenue of only ~$262M. Trailing net income is ~$65.7M, cash and short-term securities total ~$376M against ~$172.5M of 2.50% convertible notes due February 2030, and the quarterly dividend was raised 25% to $0.25 in February 2026. The June 2026 quarter is where the shine came off: sales of ~$70.4M missed guidance by ~$1.1M on a stronger dollar, Middle East export delays and cardiac allograft tissue supply, and the full-year organic growth target was cut from ~12% to ~11%. Adjusted EPS of ~$0.74 also fell short of the ~$0.81 consensus, the first miss after three quarters of beats. Shares have fallen from a 52-week high of ~$118 to $81.89 at the October 16, 2026 close, down about 19% over three months, up only about 2% year to date and down about 6% over the past year. That puts the multiple near 28 times the ~$2.89 of 2026 guided EPS. Third-quarter results are due November 4, 2026, with consensus near ~$67.4M of sales and ~$0.69 of EPS.

What's driving LeMaitre Vascular, Inc. (LMAT)?

1. Price, not volume, is the growth engine

Q2 2026 organic growth of ~10% broke down as ~7% price and ~3% units. Because most LeMaitre products are inexpensive relative to the cost of the procedure they support, list price increases have historically met little hospital resistance. Whether that continues is the single most consequential variable in the model, since a return to mid-single-digit pricing would roughly halve the company's growth rate without any change in surgical volumes.

2. Artegraft going international

The bovine carotid artery graft acquired in 2020 reached ~21% of total sales in Q2 2026 and grew ~34%. Approvals in Vietnam, Morocco and Turkey during the quarter brought the total to 56 countries, international Artegraft sales moved from ~$2.1M in Q1 to ~$2.8M in Q2, and management expects ~$11M of international sales in 2026 against ~$4M in 2025. Filings in Korea, Brazil and India are targeted for 2027.

3. A sales force being expanded into stronger territories

Headcount stood at 163 representatives with a year-end target of 170 to 180, nine already signed for Q3 and 13 openings remaining. The geographic split is telling: EMEA and Asia-Pacific each grew ~18% in the quarter while the Americas grew ~5%, so incremental hiring is aimed where the response has been strongest. Sales capacity, rather than product supply, has been the historic constraint on that expansion.

4. A net cash balance sheet with capital return started

Cash and short-term securities of ~$376M against ~$172.5M of convertible notes leaves roughly $204M of net cash on a ~$1.87B market value (October 2026). A $100M repurchase authorization runs through February 18, 2027 and has gone entirely unused so far. That capacity has historically funded small tuck-in acquisitions of vascular product lines, which is how Artegraft and the allograft operation arrived in the first place.

What are the risks to LeMaitre Vascular, Inc. (LMAT)?

Cardiac allograft growth is limited by donor tissue supply, and management is prioritizing US supply before international expansion, so that line stays capacity-bound into the second half of 2026. The North Brunswick, New Jersey facility, where the Artegraft graft that now carries ~21% of sales is processed, received additional FDA quality-system observations on June 25, 2026, with a company response filed July 16; an escalation there would reach a large share of revenue. Separately, an FDA pre-submission indicated a clinical trial is likely to be required for the QuickStitch product, on timelines measured in years, and catheter sales fell ~11% against a prior-year period inflated by post-recall stocking orders. Currency, Middle East export disruption and the tissue constraint each accounted for roughly a third of the Q2 revenue shortfall and are expected to persist through the second half. The convertible notes convert near ~$119 to ~$120 per share, which caps upside participation with dilution above that level; as of the latest filings reviewed for this page no filed securities class action, restatement or going-concern matter appears in the company's filings, and the stock's ~28 times guided 2026 earnings (about 26 times 2027 estimates) leaves limited room if pricing power narrows. The September quarter is also a seasonally soft comparison: consensus of ~$0.69 EPS for the November 4 report is below the ~$0.75 of the year-earlier quarter, so a second consecutive miss would land on a stock that has already de-rated.

What is the LeMaitre Vascular, Inc. (LMAT) forecast?

7 analysts publish price targets on LMAT, averaging $99.29 as of November 2026, or +28.9% against the $77.01 share price on November 16, 2026. The published targets run from $81.00 to $132.00, a moderate spread, and the ratings split 4 buy, 4 hold, 0 sell. Over the last six months there have been 0 raises and 3 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full LMAT forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

Is LMAT a buy or a sell?

We give no verdict on LeMaitre Vascular, Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. Price, not volume, is the growth engine. Q2 2026 organic growth of ~10% broke down as ~7% price and ~3% units. The most optimistic published target, $132.00, assumes this works close to its best case.

The case against. Cardiac allograft growth is limited by donor tissue supply, and management is prioritizing US supply before international expansion, so that line stays capacity-bound into the second half of 2026. The most pessimistic target, $81.00, is roughly what LMAT is worth if this bites instead.

Read the full bull and bear case on LMAT, including what would have to change to break either one. Walnut is not an investment adviser.

Has LeMaitre Vascular, Inc. (LMAT) split its stock?

No. LeMaitre Vascular, Inc. (LMAT) has not split its stock in the last 10 years. The statement covers only the window we check, so an older split in the company’s history is possible. It also matters less than it once did: fractional shares mean a high price per share no longer keeps smaller investors out, which removed most of the practical reason to split.

How is LeMaitre Vascular, Inc. (LMAT) valued?

Market cap, P/E and dividend yield at today's price are in the LMAT key stats above. The business figures below come from LeMaitre Vascular, Inc.'s reported results as of October 2026 and change when it next reports.

  • Revenue (TTM): ~$262M, up ~10% year over year in Q2 2026
  • Q2 2026 sales: ~$70.4M, ~10% organic (~7% price, ~3% volume)
  • Q2 2026 EPS vs estimate: ~$0.74 vs ~$0.81 consensus
  • Gross / operating margin (TTM): ~71.9% / ~29%
  • FY2026 guidance: sales ~$276.3M, ~11% organic, EPS ~$2.89, operating income ~$76.8M
  • Cash and securities vs debt / dividend: ~$376M vs ~$172.5M converts due 2030; ~$1.00 annual dividend, ~1.2% yield

As of October 2026: At $81.89 a share on October 16, 2026 and a ~$1.87B market value, LMAT carries about 7.1 times trailing sales and roughly 6.4 times sales net of its ~$204M net cash position, with a trailing P/E near 29 and a forward P/E near 26. Those are software-adjacent multiples on a $262M revenue base, sustained by 72% gross margins and a two-decade record of annual price increases rather than by growth (organic growth is guided to ~11%). The de-rating from a ~$118 high to within a few dollars of the 52-week low of ~$78.22 happened on a ~$1.1M revenue miss, an EPS miss and a one-point cut to the organic target, which is a measure of how tightly the valuation was tied to the pricing story holding. Seven covering analysts carry a mean target near $107.

Who competes with LeMaitre Vascular, Inc. (LMAT)?

Diversified device majors with vascular franchises

Becton Dickinson (the former Bard peripheral vascular lines), Medtronic, Boston Scientific, Terumo and Getinge all sell into the same operating rooms, alongside privately held W.L. Gore, whose ePTFE grafts are the default synthetic option. None of them competes across LeMaitre's whole catalogue; each overlaps on a few product families where scale in purchasing contracts matters.

Biologic and tissue specialists

Artivion processes human cardiac and vascular allografts and competes directly with LeMaitre's tissue lines, Baxter sells a bovine pericardial patch against XenoSure, Elutia supplies porcine cardiovascular patches (LeMaitre distributed them in the US until that agreement ended in May 2025), and Humacyte's bioengineered vessel targets the same vascular access and trauma cases Artegraft serves. Donor and animal tissue sourcing is the shared constraint across this group.

Endovascular substitution

The larger structural competitor is not a company but a technique. Stents, drug-coated balloons and atherectomy systems from Abbott, Boston Scientific, Medtronic and Cook keep moving peripheral cases out of open surgery, which shrinks the procedure pool for grafts, patches, shunts and valvulotomes over time. LeMaitre's answer has been price and geographic reach rather than an endovascular portfolio of its own.

What stocks are similar to LeMaitre Vascular, Inc. (LMAT)?

Other names that sit close to LMAT: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. They are useful if you want to spread one thesis across several tickers.

How to invest in LeMaitre Vascular, Inc. (LMAT)

There are three common ways to get LMAT exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so LMAT sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where LMAT fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

The bottom line on LeMaitre Vascular, Inc. (LMAT)

LeMaitre is a small, highly profitable, price-led niche surgical supplier whose 2026 stumble looks operational rather than structural, priced near 28 times guided 2026 earnings and about 26 times 2027 estimates as of October 2026 while tissue supply and export delays remain unresolved.

More on LeMaitre Vascular, Inc. (LMAT)

Whether LMAT is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is LMAT a buy or a sell?, and where the stock could go from here in the LMAT stock forecast.

For income investors, whether LMAT pays a dividend and how the payout looks is covered in does LMAT pay a dividend? And to weigh LMAT against a peer, read the full side-by-side comparisons: LMAT vs MDT and LMAT vs BSX.

Wondering how LMAT fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.

Your questions about LeMaitre Vascular, Inc.

Ask Walnut's AI anything about LMAT and see how it fits what you own.

FAQ

What does LeMaitre Vascular actually sell?

+

Devices and implants for open vascular surgery: bovine carotid artery grafts (Artegraft), biologic patches, human vascular and cardiac allografts, carotid shunts, valvulotomes, embolectomy catheters and synthetic grafts. About 163 direct representatives sell them to vascular surgeons rather than through distributors in most major markets.

Is LMAT profitable?

+

Yes, and unusually so for its size. The June 2026 quarter produced ~$20.4M of operating income on ~$70.4M of sales, a ~29% operating margin, with a ~72.1% gross margin and ~$17.1M of net income. Trailing twelve-month net income is ~$65.7M on ~$262M of revenue.

Does LMAT pay a dividend?

+

It pays ~$0.25 per quarter, or ~$1.00 annualized, a yield of roughly 1.2% at ~$82 a share (October 2026). The board raised the dividend 25% in February 2026. A separate $100M repurchase authorization runs through February 18, 2027 and had not been used as of the June 2026 quarter.

Why did the stock fall after the Q2 2026 report?

+

Sales came in ~$1.1M under guidance and the full-year organic growth target was trimmed from ~12% to ~11%. Management attributed the shortfall in roughly equal thirds to a stronger dollar, Middle East export delays and cardiac allograft tissue supply, and said all three would persist through the second half. Adjusted EPS of ~$0.74 also missed the ~$0.81 consensus. The shares have not recovered since: they closed at $81.89 on October 16, 2026, about 19% lower than three months earlier.

How much of the growth comes from price rather than volume?

+

In Q2 2026, ~7 percentage points of the ~10% organic growth came from price and ~3 from unit volume. LeMaitre's products are low-cost items within expensive procedures, which has historically made annual increases easier to pass through, so the durability of that pricing is central to the story.

How important is Artegraft to the company?

+

It reached ~21% of total sales in Q2 2026 and grew ~34%. Acquired in 2020 for ~$90M, it is now approved in 56 countries with Korea, Brazil and India targeted for 2027. Its concentration also concentrates risk: it is processed at the New Jersey facility that received FDA quality-system observations in June 2026.

Does LeMaitre carry debt?

+

It has ~$172.5M of 2.50% convertible senior notes due February 1, 2030, against ~$26.6M of cash and ~$349.6M of short-term marketable securities, so the company is in a net cash position of roughly $204M. The notes convert near ~$119 to ~$120 per share, which introduces dilution above that price.

What would someone track to follow the thesis?

+

Four things: the price component of organic growth in each quarterly release, resolution of the FDA observations at the New Jersey Artegraft facility, cardiac allograft tissue supply, and sales representative headcount against the 170 to 180 year-end target. The next update is the November 4, 2026 third-quarter report. Full-year 2026 guidance stands at ~$276.3M of sales and ~$2.89 of diluted EPS. Walnut is not an investment adviser and none of this is a recommendation.

How has LMAT stock performed in 2026?

+

LMAT closed at $81.89 on October 16, 2026, up about 2% year to date but down about 6% over the past year and about 19% over the past three months. The 52-week range runs from roughly $78.22 to $118.01, so the stock trades near the bottom of it after the August guidance trim.

When does LeMaitre report next?

+

LeMaitre will announce third-quarter 2026 results on November 4, 2026. Consensus calls for about $67.4M of sales and about $0.69 of EPS, and full-year 2026 estimates sit near $276.5M of sales and $2.88 of EPS, essentially in line with the company's guidance.

Walnut is informational, not investment advice. Financial figures on this page are approximations; always verify current numbers with LeMaitre Vascular, Inc.'s investor relations page or your broker before making investment decisions.